BMT CTN Protocol 1401

A Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma Fusions.

Below are protocol-related documents, which may be periodically updated.

             Protocol Co-Chair: David Avigan, MD

             Protocol Co-Chair: Nina Shah, MD

             Protocol Co-Chair: David Chung, MD

             Protocol Officer: Marcelo Pasquini, MD

             Medical Monitor: Marcie Riches, MD

             Protocol Coordinator: Lauren Nolley        

The BMT CTN is committed to including widespread transplant community participation in these trials. However, affiliate center applications are not currently being accepted for this study. The protocol closed to enrollment on October 12, 2018.